Uvax Bio
Kevin O'Neill is currently the Senior Vice President of Corporate Strategy at Uvax Bio, a vaccine development company. Prior to this, Kevin served as the Managing Partner at ForeRunner Strategy, a consulting firm, and held various leadership roles at Pfizer Pharmaceuticals, including Vice President of Vaccines and Global Business Manager for Pneumococcal Vaccines. Kevin holds a Bachelor's degree in Biology from Ursinus College and has received education from Harvard Business School and The Wharton School.
This person is not in any offices
Uvax Bio
Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world. Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.